Acrivon Therapeutics, Inc. (ACRV)
ACRV moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How ACRV actually reacts to news — the realized, point-in-time move the market made, measured across 309 labeled events over the last three years with zero look-ahead.
ACRV’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.06% | 31% | 298 |
| 30-min | 0.00% | 43% | 304 |
| 60-min | 0.00% | 47% | 308 |
| to close | 0.00% | 46% | 303 |
| Middle 50% of ACRV reactions | -1.77% to +1.42% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 309 |
Half of all Acrivon Therapeutics, Inc. news events land between -1.77% and +1.42% at 30 minutes.
Reaction stats as of 2026-08-31. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ACRV reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 11 | 0.00% | 55% | -2.58% |
| Rating reiterations | 43 | -0.38% | 35% | -1.23% |
Last 3 years, pulled 2026-08-31. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how ACRV ranks against every other measured name →
That’s how ACRV usually reacts — get an email when it moves on news →Email me when ACRV moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ACRV's baseline. Nothing else.
Recent ACRV events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference | Press release | GlobeNewswire | +6.28% | — | |
| Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer | Press release | GlobeNewswire | +0.49% | +2.45% | |
| Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts | Press release | GlobeNewswire | -1.52% | +6.94% | |
| Form 10-Q Acrivon Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.52% | +6.94% | |
| Form 8-K Acrivon Therapeutics, For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | -1.52% | +6.94% | |
| Form S-8 Acrivon Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | -1.52% | +6.94% | |
| Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study | Press release | GlobeNewswire | +1.86% | +1.86% | |
| Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference | Press release | GlobeNewswire | -0.29% | -2.89% | |
| Form 8-K Acrivon Therapeutics, For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | +0.65% | +1.95% | |
| Form DEFA14A Acrivon Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -0.57% | -4.57% | |
| Acrivon Therapeutics to Present at TD Cowen’s 7th Annual Oncology Innovation Summit | Press release | GlobeNewswire | -0.29% | +2.29% | |
| Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.45% | -7.82% | |
| Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts | Press release | GlobeNewswire | +2.54% | -2.54% | |
| Form 10-Q Acrivon Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +2.54% | -2.54% | |
| Form 8-K Acrivon Therapeutics, For: May 13 | SEC filing · Form 8-K | SEC EDGAR | +2.54% | -2.54% | |
| Form ARS Acrivon Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.82% | +1.65% | |
| Form DEF 14A Acrivon Therapeutics, For: Jun 17 | SEC filing · Form DEF | SEC EDGAR | +0.82% | +1.65% | |
| Form DEFA14A Acrivon Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +0.82% | +1.65% | |
| Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities | Press release | GlobeNewswire | +1.69% | +4.49% | |
| Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.59% | -1.18% | |
| Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | Press release | GlobeNewswire | -0.63% | +7.59% | |
| Form 10-K Acrivon Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.63% | +7.59% | |
| Form 8-K Acrivon Therapeutics, For: Mar 19 | SEC filing · Form 8-K | SEC EDGAR | -0.63% | +7.59% | |
| Form S-8 Acrivon Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | -0.63% | +7.59% | |
| Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors | Press release | GlobeNewswire | -1.81% | -1.21% | |
| Form 8-K Acrivon Therapeutics, For: Feb 25 | SEC filing · Form 8-K | SEC EDGAR | -2.03% | +12.84% | |
| Form 8-K Acrivon Therapeutics, For: Feb 27 | SEC filing · Form 8-K | SEC EDGAR | -2.51% | -15.64% | |
| Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference | Press release | GlobeNewswire | +3.33% | +0.00% | |
| Key Opinion Leader (KOL) Panel to Discuss Acrivon’s ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress | Press release | GlobeNewswire | -0.41% | -3.23% | |
| Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory | Press release | GlobeNewswire | -1.84% | -2.45% | |
| Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment | Press release | PR Newswire | — | — | |
| Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment | Press release | PR Newswire | -3.50% | -5.50% | |
| Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress | Press release | GlobeNewswire | +0.05% | +0.49% | |
| Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 | Press release | GlobeNewswire | -18.57% | -31.07% | |
| Form 8-K Acrivon Therapeutics, For: Jan 08 | SEC filing · Form 8-K | SEC EDGAR | -18.57% | -31.07% | |
| Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast | Press release | GlobeNewswire | -1.28% | +28.09% | |
| Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates | Press release | GlobeNewswire | +2.06% | -4.54% | |
| UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast | Press release | GlobeNewswire | +0.81% | -6.86% | |
| Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.54% | +1.09% | |
| Form 8-K Acrivon Therapeutics, For: Sep 05 | SEC filing · Form 8-K | SEC EDGAR | -3.03% | +19.33% | |
| Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights | Press release | GlobeNewswire | -3.65% | +1.46% | |
| Form 10-Q Acrivon Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -3.65% | +1.46% | |
| Form 8-K Acrivon Therapeutics, For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | -3.65% | +1.46% | |
| Form 8-K Acrivon Therapeutics, For: Jun 13 | SEC filing · Form 8-K | SEC EDGAR | -3.63% | -1.61% | |
| Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights | Press release | GlobeNewswire | -3.07% | -3.51% | |
| Form 10-Q Acrivon Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -3.07% | -3.51% | |
| Form 8-K Acrivon Therapeutics, For: May 14 | SEC filing · Form 8-K | SEC EDGAR | -3.07% | -3.51% | |
| Form S-8 Acrivon Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | -3.07% | -3.51% | |
| Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025 | Press release | GlobeNewswire | -8.21% | -18.41% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ACRV section they belong to.
Where else ACRV is measured.
ACRV earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Acrivon Therapeutics, Inc.'s median reaction calculated?
Every labeled ACRV news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 309 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 43% of ACRV's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-08-31.
Does ACRV's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.